The Pharmacy Times® Dermatology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of skin disorders, including psoriasis, atopic dermatitis, eczema, and acne.
September 12th 2025
Investigators from the phase 3 COAST 1 trial demonstrated the efficacy and safety of amlitelimab in patients with moderate-to-severe atopic dermatitis.
Regeneron, Sanofi Announce Positive Results for Dupilumab for Infants, Children
December 14th 2021The data presented shows that at 16 weeks, individuals who added the atopic dermatitis drug to low potency standard-of-care topical corticosteroids experienced 28% achieved clear or almost-clear skin.
Read More